Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fibroblast screening for chaperone therapy in beta-galactosidosis.

Brain & development - 1 Sept 2006

Iwasaki Hiroyuki, Watanabe Hiroshi, Iida Masami, Ogawa Seiichiro, Tabe Miho, Higaki Katsumi, Nanba Eiji, Suzuki Yoshiyuki

Abstract excerpt

We performed screening of beta-galactosidase-deficient fibroblasts for possible chemical chaperone therapy using N-octyl-4-epi-beta-valienamine (NOEV) in patients with GM1-gangliosidosis and Morquio B disease (beta-galactosidosis). Fibroblasts were cultured with NOEV for 4 days and beta-galactosidase activity was measured. Mutation analysis was performed simultaneously. Two separate criteria were set for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arginine
Share to beta-Galactosidase
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibroblasts

Share to Gangliosidosis, GM1

Share to Glutamine

Share to Molecular Chaperones

Share to Mucopolysaccharidosis IV

Source

Identifiers

PMID: 16617000
DOI: 10.1016/j.braindev.2006.02.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fibroblast screening for chaperone therapy in beta-galactosidosis.PMID 16617000Read ↗

Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts.Semantic proximity Read ↗

Beta-galactosidase deficiency: an approach to chaperone therapy.Semantic proximity Read ↗

Chemical chaperone therapy: luciferase assay for screening of β-galactosidase mutations.Semantic proximity Read ↗

Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis.Semantic proximity Read ↗

N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher diseaseSemantic proximity Read ↗

Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease.Semantic proximity Read ↗

Galactonojirimycin derivatives restore mutant human beta-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse.Semantic proximity Read ↗

Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.Semantic proximity Read ↗

The pharmacological chaperone N-n-butyl-deoxygalactonojirimycin enhances β-galactosidase processing and activity in fibroblasts of a patient with infantile GM1-gangliosidosis.Semantic proximity Read ↗

The pharmacological chaperone effect of N-octyl-beta-valienamine on human mutant acid beta-glucosidases.Semantic proximity Read ↗

Enzyme enhancement activity of N-octyl-beta-valienamine on beta-glucosidase mutants associated with Gaucher disease.Semantic proximity Read ↗

The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.